Monday July 16, 2018
Home India India Is Deve...

India Is Developing Technologies To Launch Manned Mission

The state-run ISRO’s technology demonstrator is the first in a series of tests to qualify as a crew escape system, critical for a manned mission.

0
//
15
India’s dream to put a man in space
India’s dream to put a man in space. Pixabay
Republish
Reprint

India is developing critical technologies for launching manned missions in space and preparing a document on it, a top official said on Saturday.

“Critical technologies are being developed for our human space programme as it is India’s dream to put a man in space. A mission document is in the making,” Indian Space Research Organisation (ISRO) Chairman K. Sivan told the media at an aerospace event here.

Citing the space agency’s successful maiden unmanned pad abort test on Thursday at its Sriharikota spaceport in Andhra Pradesh for the safe escape of the crew in an emergency, Sivan said that very complex technology was used for the trial, with a unique motor for fast-burning.

“The technology is very essential for our manned missions in the future, as the motor’s performance was very good. Using aerodynamics, the module was turned in a favourable direction to open the parachutes,” he said.

The state-run ISRO’s technology demonstrator is the first in a series of tests to qualify as a crew escape system, critical for a manned mission.

“We are only in the preparation stage. We need to develop much more. We are in the process of refining a document on the manned mission for review and interactions with stakeholders, including the Indian Air Force (IAF) and Hindustan Aeronautics Ltd (HAL),” said Sivan.

The crew escape system is an emergency escape measure designed to quickly pull the crew module along with the astronauts to a safe distance from the launch vehicle in the event of a launch abort.

The first pad abort test demonstrated the safe recovery of the crew module in case of any exigency at the launch pad,” ISRO said in a statement earlier.

Admitting that the scientists had to work on the next strategy for the manned mission testing, Sivan said ISRO’s work was two-pronged, with one on approved projects and the other for research and development (R&D).

The first pad abort test demonstrated the safe recovery of the crew module in case of any exigency at the launch pad,” ISRO said in a statement earlier.
The first pad abort test demonstrated the safe recovery of the crew module in case of any exigency at the launch pad,” ISRO said in a statement earlier. Flickr

“The pad abort test for the crew escape system is part of our R&D work,” he noted. The space agency also tested five new technologies during the pad abort test, as part of its strategy to develop long-term technologies.

“We and the government work on a three-year plan, with a seven-year strategy and a 15-year vision,” asserted Sivan.

Noting that space tourism would happen in the near future, the rocket scientist said it would take at least 15 years to develop the vehicle to go to space and return to the earth.

“We are not close to that. We need to work a lot towards achieving the dream of putting a man into space,” added Sivan.

After a five-hour countdown, the crew escape system lifted off with the 12.6 tonne simulated crew module from the spaceport and plunged into the sea (Bay of Bengal) 4 minutes and 19 seconds later with two parachutes, around 2.9 km away from Sriharikota, about 90km northeast of Chennai.

Also read: NASA Scientists Map Water on Moon Using India’s Chandrayaan-1 Spacecraft!

“The crew module soared 2.7 km altitude on thrust of its seven solid motors without exceeding the safe G (gravity) levels,” added the statement. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)